HC Wainwright Reaffirms Buy Rating for scPharmaceuticals (NASDAQ:SCPH)

HC Wainwright reaffirmed their buy rating on shares of scPharmaceuticals (NASDAQ:SCPH) in a report released on Thursday,Benzinga reports. The firm currently has a $18.00 target price on the stock.

Separately, Craig Hallum lowered their price target on scPharmaceuticals from $16.00 to $12.00 and set a “buy” rating on the stock in a report on Thursday.

scPharmaceuticals Trading Up 3.0 %

Shares of SCPH stock opened at $3.46 on Thursday. scPharmaceuticals has a 12 month low of $3.08 and a 12 month high of $6.71. The company has a quick ratio of 3.66, a current ratio of 8.08 and a debt-to-equity ratio of 1.66. The business’s 50 day moving average is $4.46 and its two-hundred day moving average is $4.48. The company has a market cap of $173.14 million, a PE ratio of -1.82 and a beta of 0.15.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets lifted its holdings in shares of scPharmaceuticals by 116.9% during the third quarter. BNP Paribas Financial Markets now owns 5,753 shares of the company’s stock valued at $26,000 after acquiring an additional 3,101 shares during the period. The Manufacturers Life Insurance Company bought a new position in shares of scPharmaceuticals during the third quarter valued at $57,000. MetLife Investment Management LLC lifted its holdings in shares of scPharmaceuticals by 135.0% during the third quarter. MetLife Investment Management LLC now owns 16,974 shares of the company’s stock valued at $77,000 after acquiring an additional 9,752 shares during the period. Virtu Financial LLC bought a new position in shares of scPharmaceuticals during the first quarter valued at $90,000. Finally, Captrust Financial Advisors lifted its holdings in shares of scPharmaceuticals by 32.2% during the third quarter. Captrust Financial Advisors now owns 18,539 shares of the company’s stock valued at $85,000 after acquiring an additional 4,513 shares during the period. 89.52% of the stock is owned by institutional investors.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.